Voyager Therapeutics, Inc. (VYGR) - Company Net Income

Official company branding of voyagertherapeutics.com (VYGR)

Voyager Therapeutics (VYGR) focuses on gene therapy, implementing environmental standards for chemical reagent recycling and modernizing its laboratories. The business is scaling the TRACER system for CNS treatment, monetizing the technology through B2B agreements with industry behemoths. This price chart on GURU.Markets clearly demonstrates the changes and confirms that the separate_profit metric is -0.11, supporting the financial results of the issuer VYGR.

Net Income: Voyager Therapeutics, Inc. (VYGR) for 07/04/2022 - 11/01/2026

Financial and market metric breakdowns for Voyager Therapeutics, Inc. (VYGR)

- stock value and consensus price forecast:
Market Price Voyager Corp|VYGR - Consensus Target
- market capitalization indicators:
Market Value Voyager Corp|VYGR - Total Company Value
- book capitalization indicators:
Net Asset Value per Share Voyager Therapeutics|VYGR - Company Net Assets|Market-to-Book Ratio voyagertherapeutics.com|VYGR - Company Total Assets
- debt and liquidity details:
Total Debt to Capital Voyager Therapeutics|VYGR - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Voyager Therapeutics Inc|VYGR - Company Aggregate Debts|Debts to Book Value Voyager Corp|VYGR - Company Long-Term Debt|Company Short-Term Loans and Borrowings Voyager Therapeutics|Intermediate Coverage Ratio voyagertherapeutics.com
- company profitability and valuation multiples indicators:
VYGR - Net Income
Fundamental valuation:VYGR Voyager Corp
Manufactured product of Voyager Therapeutics, Inc.

For Voyager Therapeutics (VYGR), the company's cash profit reflects financial stability against the risks of developing complex brain drugs. This indicator calculates net daily earnings, neutralizing temporary distortions from one-off trades by major players. Analyzing this cash profit allows for the distinction between fundamental growth and random spikes. Purchasing assets at historical peaks of this metric risks a deep portfolio drawdown. A stable trend confirms the viability of the business model and the reliability of partnership agreements.

Main competitors

Company Net Income Biogen Idec (BIIB)|Net Income NBIX|Company Net Income RGC|Company Net Income Axsome Therapeutics, Inc. (AXSM)|ACAD - Company Net Income|Xenon Pharmaceuticals Inc - Net Income|Viking Therapeutics Corp (VKTX) - Company Net Income|Supernus Pharmaceuticals - Net Profit|CPRX - Net Profit|DNLI: Net Profit|Annual Net Income Harmony Biosciences Inc HRMY|BHVN (Biohaven Pharmaceutical) - Net Profit|Company Net Income Amylyx Corp AMLX|Company Net Income Trevi Therapeutics (TRVI)|PRAX (praxismedicines.com) - Final Profit|Anavex Life Sciences Corp. - Net Income|Final Profit CBLL|PRTA: Net Income|Alector, Inc. - Profit After Payment of Taxes|ANNX: Net Profit|Omeros - Final Profit|NGNE (Neurogene) - Net Profit|Company Net Income AC Immune S.A. ACIU|Company Net Income Neumora Therapeutics Inc (NMRA)|SCLX (Scilex Holding Company, Inc.) - Final Profit|Net Profit TVGN (Tevogen Bio Holdings)|Net Profit Alpha Cognition Inc ACOG|CGTX - Company Net Income|Profit After Tax IKT|SAVA: Net Profit|Company Net Income Assertio (ASRT)|Net Income COYA|Net Profit VistaGen Therapeutics Inc|Net Income OVID (Ovid Therapeutics Inc.)|Profit After Payment of Taxes ABOS|Net Profit CRVO (CervoMed Inc)|Net Financial Result Alterity Therapeutics Ltd. (ATHE)|Clene Nanomedicine - Net Profit|PepGen Inc. (PEPG) - Net Income|Jupiter Neurosciences Inc (JUNS) - Company Net Income|RLMD - Net Financial Result|Net Income ANVS|Company Net Income GRCE|Net Income AIFF (Firefly Neuroscience, Inc)|KLTO - Company Net Income|Net Profit NRSN (NeuroSense Therapeutics Ltd.)|Annual Net Income Reviva Pharmaceuticals Holdings Inc.|MTVA - Company Net Income|Final Profit NRXS (NeurAxis Inc)|heliusmedical.com (HSDT) - Company Net Income|Company Profit PASG|NEUP (Neuphoria Therapeutics, Inc.) - Net Profit|Company Net Income Minerva Neurosciences Inc NERV|Net Income ATHA (Athira)|Net Profit Addex (ADXN)|Company Net Income Alzamend Neuro ALZN|Final Profit CYCN|PTIX - Company Net Income|Company Net Income Pasithea Therapeutics|CRGT (cortigent.com) - Net Income|ATXI (Avenue Therapeutics Inc) - Company Net Income|Company Net Income Brainstorm Cell|Company Net Income caratherapeutics.com CARA|Net Income CHRO (Chromocell Therapeutics Corp.)|ELYM - Company Net Income|Net Profit ITCI (Intra-Cellular Therapies, Inc.)|Net Profit Longboard LBPH|Marinus Pharmaceuticals - Net Profit|Annual Net Income nkgenbiotech.com (NKGN)|NRBO: Net Profit|Company Net Income Sage Therapeutics Inc. (SAGE)|Company Net Income Neurotrope|TRVN: Final Profit|Net Income VIGL (Vigil Neuroscience)|WENA (Anew Medical Inc.) - Final Profit|Cerevel Therapeutics, Inc. - Net Income